CEBPA基因突变与急性髓系白血病临床特点及预后关系

张梦娜; 杨艳丽; 耿英华; 李骏; 冯会欣

doi:10.13201/j.issn.1004-2806.2021.09.012

CEBPA基因突变与急性髓系白血病临床特点及预后关系

- 蚌埠医学院第一附属医院血液内科(安徽蚌埠, 233000)
基金项目:
安徽省高校自然科学研究重点项目(No:KJ2019A0375)

安徽省科技发展基金项目(No:BYKF1885)

详细信息

通讯作者: 杨艳丽,E-mail:yangyanli0702@126.com

中图分类号: R733.71

收稿日期: 2021-04-18

Relationship between CEBPA gene mutation and clinical characteristics and prognosis of acute myeloid leukemia

- Department of Hematology, the First Hospital of Bengbu Medical College, Bengbu, 233000, China

More Information

Corresponding author: YANG Yanli, E-mail: yangyanli0702@126.com

Received Date: 18 April 2021

摘要

摘要: 目的:探讨CEBPA基因突变与急性髓系白血病(AML)临床特征及预后的关系。方法:收集2018年1月1日—2020年1月1日初次就诊于我院的154例AML患者(排除M3型)的详细信息,其中CEBPA双突变(CEBPA^dm)23例,CEBPA单突变(CEBPA^sm)8例,CEBPA突变阴性(CEBPA^-)123例。对AML患者的临床特征及预后进行回顾性分析,比较3组患者间完全缓解(CR)率、总生存期(OS)和无进展生存时间(PFS)。结果:与CEBPA^-组比较,CEBPA^dm组初诊年龄小(P=0.002),血小板计数低(P<0.001)、血红蛋白高(P=0.030)、白细胞计数高(P=0.041),2组间性别分布、骨髓原始细胞计数差异无统计学意义;CEBPA^dm组FAB分型多为M2型(P=0.001),染色体核型多为正常核型(P=0.001),CEBPA^-组M5型多于CEBPA^dm组(P=0.016)。CEBPA^dm组多表达CD7(P<0.001),其余免疫表型CD13、CD15、CD33、CD38、CD117、HLA-DR、CD56在2组分布中差异无统计学意义。CEBPA^dm、CEBPA^-、CEBPA^sm三组比较,CEBPA^dm多合并WT1基因突变(P=0.006),CEBPA^sm组TET基因突变多于CEBPA^dm组(P=0.027),NPM1、FLT3基因突变在3组分布中差异无统计学意义;CEBPA^dm组首次CR率及总CR率均明显高于CEBPA^sm组及CEBPA^-组(P<0.001,P<0.001),且OS(60个月,95%CI 28.115~91.885个月)和PFS(53个月,95%CI 4.664~101.336个月)较其余2组均明显延长(均P<0.05),而CEBPA^sm组在预后上并没有这种优势,与CEBPA^-组比较差异无统计学意义。结论:CEBPA^dm组初诊年龄小、血小板计数低、血红蛋白高、白细胞计数高;FAB分型多为M2型,染色体核型多为正常核型;多合并WT1基因突变;CR率高,OS、PFS明显延长,治疗效果好,预后良好。
- 急性髓系白血病 /
- CEBPA基因突变 /
- 临床特点 /
- 预后
Abstract: Objective: To explore the relationship between CEBPA gene mutation and clinical features and prognosis of patients with acute myeloid leukemia(AML).Methods: From January 1, 2018 to January 1, 2020, the detailed information of 154 AML patients(excluding M3 type) was collected, including 23 cases of CEBPA double mutation(CEBPA^dm), 8 cases of CEBPA single mutation(CEBPA^sm) and 123 cases of CEBPA mutation negative(CEBPA^-). The clinical features and prognosis of AML patients were retrospectively analyzed, and the complete response(CR) rate, overall survival(OS) and progression-free survival(PFS) of the 3 groups were compared.Results: Compared with CEBPA^- group, the CEBPA^dm group had a younger age at first diagnosis(P=0.002), lower platelet count(P<0.001), higher hemoglobin(P=0.030) and higher white blood cell count(P=0.041). There was no significant difference in sex and bone marrow primitive cell count between the 2 groups. The FAB classification of the CEBPA^dm group was M2(P=0.001), the karyotype was normal(P=0.001), M5 type was higher in CEBPA^- group than that in the CEBPA^dm group(P=0.016). CEBPA^dm group mostly expressed CD7(P<0.001), but there was no significant difference in the distribution of other immunophenotypes CD13, CD15, CD33, CD38, CD117, HLA-DR and CD56 between the 2 groups. Compared with CEBPA^-and CEBPA^sm group, CEBPA^dm group mostly combined with WT1 gene mutation(P=0.006), the mutation of TET gene in CEBPA^sm group was more than that in CEBPA^dm group(P=0.027), and there was no significant difference in the distribution of NPM1 and FLT3 gene mutations among the 3 groups. The first CR rate and total CR rate in CEBPA^dm group were significantly higher than those in CEBPA^sm group and CEBPA^- group(P<0.001, P<0.001), and the OS(60 months, 95%CI 28.115-91.885 months) and PFS(53 months, 95%CI 4.664-101.336 months) in CEBPA^dm group were significantly higher than those in CEBPA^sm group and CEBPA^- group(P<0.05).Conclusion: Patients in the CEBPA^dm group are young at first diagnosis, wiht low platelet count, high hemoglobin and high white blood cell count. FAB typing is mostly M2 type, and chromosome karyotype is mostly normal karyotype. WT1 gene mutation is found in most patients. The CR rate is high, the OS and PFS are obviously prolonged, and the treatment effect and the prognosis is good.
- acute myeloid leukemia /
- CEBPA gene mutation /
- clinical characteristics /
- prognosis

HTML全文

参考文献(19)

[1]	沈杨.分子靶向药物在老年急性髓性白血病中的应用[J].临床血液学杂志,2020,33(5):302-306.
[2]	Dinmohamed AG,Visser O,van Norden Y,et al.Treatment,trial participation and survival in adult acute myeloid leukemia:a population-based study in the Netherlands,1989-2012[J].Leukemia,2016,30(1):24-31.
[3]	Schmidt L,Heyes E,Grebien F.Gain-of-Function Effects of N-Terminal CEBPA Mutations in Acute Myeloid Leukemia[J].Bioessays,2020,42(2):e1900178.
[4]	沈悌,赵永强.血液病诊断及疗效标准[M].4版.北京:科学出版社,2018:91-93.
[5]	Su L,Gao S,Liu X,et al.CEBPA mutations in patients with de novo acute myeloid leukemia:data analysis in a Chinese population[J].Onco Targets Ther,2016,9:3399-3403.
[6]	Li Y,Lv X,Ge X,et al.Mutational spectrum and associations with clinical features in patients with acute myeloid leukaemia based on next generation sequencing[J].Mol Med Rep,2019,19(5):4147-4158.
[7]	De Kouchkovsky I,Abdul-Hay M.'Acute myeloid leukemia:a comprehensive review and 2016 update'[J].Blood Cancer J,2016,6(7):e441.
[8]	金洁.急性髓细胞白血病的新药治疗[J].临床血液学杂志,2019,32(3):174-176.
[9]	郑琳.CEBPA基因双突变急性髓系白血病患者的临床特征及预后因素分析[D].吉林:吉林大学,2020.
[10]	Pundhir S,Bratt Lauridsen FK,Schuster MB,et al.Enhancer and Transcription Factor Dynamics during Myeloid Differentiation Reveal an Early Differentiation Block in Cebpa null Progenitors[J].Cell Rep,2018,23(9):2744-2757.
[11]	Wilhelmson AS,Porse BT.CCAAT enhancer binding protein alpha(CEBPA)biallelic acute myeloid leukaemia:cooperating lesions,molecular mechanisms and clinical relevance[J].Br J Haematol,2020,190(4):495-507.
[12]	Lin LI,Chen CY,Lin DT,et al.Characterization of CEBPA mutations in acute myeloid leukemia:most patients with CEBPA mutations have biallelic mutations and show a distinct immunophenotype of the leukemic cells[J].Clin Cancer Res,2005,11(4):1372-1379.
[13]	Mannelli F,Ponziani V,Bencini S,et al.CEBPA-double-mutated acute myeloid leukemia displays a unique phenotypic profile:a reliable screening method and insight into biological features[J].Haematologica,2017,102(3):529-540.
[14]	师锦宁,朱雨,洪鸣,等.急性髓细胞白血病患者基于遗传学突变的预后分析[J].中华医学遗传学杂志,2017,34(6):806-811.
[15]	朱名俣,朱颖,陈蓉蓉,等.CD7在CEBPA野生型和突变型急性髓系白血病患者中的表达及其预后意义[J].中华血液学杂志,2020,41(2):100-105.
[16]	Arber DA,Orazi A,Hasserjian R,et al.The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia[J].Blood,2016,127(20):2391-2405.
[17]	Taskesen E,Bullinger L,Corbacioglu A,et al.Prognostic impact,concurrent genetic mutations,and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients:further evidence for CEBPA double mutant AML as a distinctive disease entity[J].Blood,2011,117(8):2469-2475.
[18]	Metzeler KH,Herold T,Rothenberg-Thurley M,et al.Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia[J].Blood,2016,128(5):686-698.
[19]	Wang H,Chu TT,Han SY,et al.FLT3-ITD and CEBPA Mutations Predict Prognosis in Acute Myelogenous Leukemia Irrespective of Hematopoietic Stem Cell Transplantation[J].Biol Blood Marrow Transplant,2019,25(5):941-948.